A multinational drugmaker is paying 45 states including South Dakota $105 million to settle complaints that the company unlawfully marketed three drugs.
South Dakota Attorney General Marty Jackley says South Dakota's share of the settlement is nearly $1.2 million.
The settlement resolves allegations that London-based Glaxo illegally marketed Advair, Paxil and Wellbutrin for purposes that had not been approved by the Food and Drug Administration. Once the FDA approves a drug as safe and effective, a manufacturer cannot market or promote that drug for an unapproved use, a practice called off-label marketing.
The asthma treatment Advair is Glaxo's best-selling product. Paxil and Wellbutrin are antidepressant drugs.
Most Popular Today
- 1.Your Money Matters
Consumer Warning: Watch Your Bank Account For Small Fraudulent Charges At Walmart
- 2.Education Funding
Mitchell School Board Meets As Superintendent Defends 'Second Job'
Windom Beef Plant Closing
InBev, SABMiller Close To Beer Merger
Retailers Taking Applications For Seasonal Jobs
Head of TSA Talks Security at Sioux Falls Regional Airport
- 7.Retail & Restaurants
Empire Mall To Hold Holiday Job Fair
Administrator: TSA Needs To Refocus Mission On Security
Rapid City Mayor Proposes Plan To Boost President's Plaza
Monday Afternoon Business Brief